New cell therapy shows promise for Hard-to-Treat myeloma
Disease control
Completed
This early-stage study tested a new cell therapy called FT576, given alone or with another drug (daratumumab), in 31 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goals were to find the safest dose and check for side effects. …
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC